Search Results for: jennifer lockwood

340B INDUSTRY LEADER SPOTLIGHT

Jennifer Lockwood, CEO/Founder, Ravin Consultants

In Industry Leader Spotlight, Sponsored ContentAugust 5, 2021573 Views

Q: Where did you grow up?

I grew up in Scranton and Mechanicsburg, Pennsylvania and regularly traveled from Pittsburgh to Philly. My mom was a registered nurse, and I would

…

The Potential Domino Effect of Tennessee’s HIV Federal Funding Cuts

In Sponsored ContentFebruary 2, 20231089 Views

AIDS Advocates Holding Weeklong Protest Over Gilead’s 340B Contract Pharmacy Restrictions and Changes In Patient Assistance Program

In Pharma IndustryOctober 27, 2022457 Views

Laura Gilcrest

AIDS advocates with placards protesting Gilead policy

AIDS advocates are holding a week long series of protests outside Gilead's California headquarters.

AIDS Healthcare Foundation (AHF) members are staging a weeklong, twice-daily series of protests at drug maker Gilead Science’s Northern California headquarters to protest the company’s policy to impose conditions on 340B providers that use contract pharmacies to dispense

…

Lifting of Title X Gag Rule Could Spur Hundreds of Clinics to Rejoin 340B

In Federal, RegulatoryOctober 12, 20211672 Views

Ron Shinkman

A September 2019 protest in Cleveland against the Trump administration rule barring Title X-funded family clinics from providing abortion referrals.

Hundreds of family planning clinics that lost their Title X federal grants and 340B eligibility because they opposed a Trump-era rule barring them from providing abortion referrals might return to Title X and 340B soon.

The U.S. Department

…

340B Providers Might Insure HIV-at-Risk Patients in Response to Gilead’s PrEP Reimbursement Cuts

In Pharma IndustryOctober 5, 2021895 Views

Ron Shinkman

340B covered entities are bracing for a huge reimbursement cut due to start in January for Gilead pre-exposure prophylaxis (PrEP) medications.

340B covered entities are exploring buying health insurance for patients at risk of contracting HIV in response to a huge reimbursement cut due to start in January for Gilead pre-exposure prophylaxis (PrEP) medications.

Gilead announced in April

…